Patents by Inventor Stephan D. Parent

Stephan D. Parent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of a pyrrolopyridine-aniline compound
    Patent number: 12649742
    Abstract: The present disclosure provides crystalline forms of the compound having formula (I): (I), wherein the crystalline forms are crystalline Forms A, B, C, E, F, and H, each of which is characterized by an X-ray powder diffraction (XRPD) pattern. The present disclosure also provides methods for preparing crystalline forms, in particular Form A. The present disclosure further provides methods of treating various skin disorders using the crystalline forms of the disclosure or a pharmaceutical composition thereof.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: June 9, 2026
    Assignee: NFLECTION THERAPEUTICS, INC.
    Inventors: Stephan D. Parent, Courtney S. Johnson, John Kincaid
  • SALTS OF AN ANTIOXIDANT AND CRYSTALLINE FORMS THEREOF
    Publication number: 20250388550
    Abstract: The present disclosure is directed to salt forms of L-Ergothioneine and crystalline forms thereof, and processes for their preparation. Also provided is a crystalline form of L#Ergothioneine (Form C) and a crystalline form of DL-Ergothioneine (Form A).
    Type: Application
    Filed: June 30, 2023
    Publication date: December 25, 2025
    Inventors: Jan Trampota, Stephan D. Parent, Travis Lee Houston
  • PROCESSES FOR PREPARING SOLID STATE FORMS
    Publication number: 20250360110
    Abstract: The present disclosure is related to a polymorphic form of ritonavir prepared by novel methods that require less time to produce the polymorphic form, the methods of preparing the polymorphic form, pharmaceutical compositions comprising the polymorphic form produced by the provided methods, and corresponding methods of treatment with the polymorphic form produced by the provided methods.
    Type: Application
    Filed: April 29, 2025
    Publication date: November 27, 2025
    Inventors: Adrian RADOCEA, Jordan Michael CROOM, Larry Robin CHAN, Ami Sanat BHAVSAR, Pamela A. SMITH, Stephen R. BYRN, Stephan D. PARENT, Dale K. PURCELL
  • Solid forms of a modulator of hemoglobin
    Patent number: 12473277
    Abstract: Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: November 18, 2025
    Assignee: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Stephan D. Parent, Travis Lee Houston, Courtney S. Johnson, Fang Wang
  • Salt and crystal form of compound having agonistic activity to S1P5 receptor
    Patent number: 12459890
    Abstract: Compound I as defined, having high S1P5 receptor-selective agonist activity on the S1P1 receptor, and the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof are provided as drug substances of pharmaceuticals.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: November 4, 2025
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shuhei Otani, Takayuki Fujito, Naoko Imura, Hideomi Kijima, Stephan D. Parent, Melanie Janelle Bevill, Courtney S. Johnson, Travis Lee Houston
  • INHIBITORS OF THE MENIN-MLL INTERACTION
    Publication number: 20250326764
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: April 16, 2025
    Publication date: October 23, 2025
    Inventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
  • Crystalline salts of psilocin
    Patent number: 12358873
    Abstract: Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.
    Type: Grant
    Filed: February 29, 2024
    Date of Patent: July 15, 2025
    Assignee: Canna-Chemistries LLC
    Inventors: Nate Schultheiss, Travis Lee Houston, Stephan D. Parent
  • Salt forms and solvates of Mcl-1 antagonists
    Patent number: 12351588
    Abstract: Disclosed herein are salt and solvate forms of. (1S,3?R,6?R,7?S,8?E,11?S,12?R)-6-chloro-7?-methoxy-11?,12?-dimethyl-3,4-dihydro-2H,15?H-spiro[naphthalene-1,22?-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15?-one 13?,13?-dioxide (AMG 176): such as crystalline salt and solvate forms thereof. Also disclosed are methods of making the salt and solvate forms, and methods of treating diseases and disorders with the salt and solvate forms.
    Type: Grant
    Filed: April 5, 2023
    Date of Patent: July 8, 2025
    Assignee: AMGEN INC.
    Inventors: Henry Morrison, Jason S. Tedrow, Stephan D. Parent, Courtney Johnson, Travis Houston, Melanie Bevill
  • CRYSTALLINE FORMS OF A PYRROLOPYRIDINE-ANILINE COMPOUND
    Publication number: 20250179062
    Abstract: The present disclosure provides crystalline forms of the compound having formula (I): (I), wherein the crystalline forms are crystalline Forms A, B, C, E, F, and H, each of which is characterized by an X-ray powder diffraction (XRPD) pattern. The present disclosure also provides methods for preparing crystalline forms, in particular Form A. The present disclosure further provides methods of treating various skin disorders using the crystalline forms of the disclosure or a pharmaceutical composition thereof.
    Type: Application
    Filed: January 20, 2022
    Publication date: June 5, 2025
    Inventors: Stephan D. PARENT, Courtney S. JOHNSON, John KINCAID
  • Processes for preparing solid state forms
    Patent number: 12318370
    Abstract: The present disclosure is related to a polymorphic form of ritonavir prepared by novel methods that require less time to produce the polymorphic form, the methods of preparing the polymorphic form, pharmaceutical compositions comprising the polymorphic form produced by the provided methods, and corresponding methods of treatment with the polymorphic form produced by the provided methods.
    Type: Grant
    Filed: March 29, 2024
    Date of Patent: June 3, 2025
    Assignee: Varda Space Industries, Inc.
    Inventors: Adrian Radocea, Jordan Michael Croom, Larry Robin Chan, Ami Sanat Bhavsar, Pamela A. Smith, Stephen R. Byrn, Stephan D. Parent, Dale K. Purcell
  • Inhibitors of the menin-MLL interaction
    Patent number: 12312359
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: May 27, 2025
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • Solid state forms
    Patent number: 12252486
    Abstract: The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: March 18, 2025
    Assignee: Amgen Inc.
    Inventors: Mary Chaves, Ron C. Kelly, Prashant Agarwal, Stephan D. Parent, Darren Leonard Reid, Roman Shimanovich
  • CRYSTALLINE FORMS OF PENTAAZA MACROCYCLIC RING COMPLEX
    Publication number: 20250073244
    Abstract: The present invention provides crystalline forms of a pentaaza macrocyclic ring complex according to the following formula: Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of disease states.
    Type: Application
    Filed: March 7, 2024
    Publication date: March 6, 2025
    Inventors: Jeffrey A. SCHOLTEN, Stephan D. PARENT, Yike SI, Tianjing ZHAO, Xiaoyang WANG, Travis L. HOUSTON
  • Crystalline Polymorphs of the Free Base of 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
    Publication number: 20250032471
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Application
    Filed: October 10, 2024
    Publication date: January 30, 2025
    Inventors: Zhe LI, Stephan D. PARENT, Travis HOUSTON
  • CRYSTALLINE FORMS OF PENTAAZA MACROCYCLIC RING COMPLEX
    Publication number: 20240300988
    Abstract: The present disclosure provides polymorph forms of pentaaza macrocyclic ring Also provided are pharmaceutical compositions that include the provided polymorph forms and methods of using the provided polymorph forms and pharmaceutical compositions for the treatment of disease states.
    Type: Application
    Filed: March 7, 2024
    Publication date: September 12, 2024
    Inventors: Stephan D. PARENT, Tanise SHATTOCK-GORDON
  • CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR
    Publication number: 20240300897
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Application
    Filed: May 7, 2024
    Publication date: September 12, 2024
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • PROCESSES FOR PREPARING SOLID STATE FORMS
    Publication number: 20240269118
    Abstract: The present disclosure is related to a polymorphic form of ritonavir prepared by novel methods that require less time to produce the polymorphic form, the methods of preparing the polymorphic form, pharmaceutical compositions comprising the polymorphic form produced by the provided methods, and corresponding methods of treatment with the polymorphic form produced by the provided methods.
    Type: Application
    Filed: March 29, 2024
    Publication date: August 15, 2024
    Inventors: Adrian RADOCEA, Jordan Michael CROOM, Larry Robin CHAN, Ami Sanat BHAVSAR, Pamela A. SMITH, Stephen R. BYRN, Stephan D. PARENT, Dale K. PURCELL
  • CRYSTALLINE SALTS OF PSILOCIN
    Publication number: 20240246912
    Abstract: Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.
    Type: Application
    Filed: February 29, 2024
    Publication date: July 25, 2024
    Inventors: Nate Schultheiss, Travis Lee Houston, Stephan D. Parent
  • Crystalline forms and salt forms of a kinase inhibitor
    Patent number: 12017995
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 25, 2024
    Assignee: Exelixis, Inc.
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • SOLID FORMS OF A MODULATOR OF HEMOGLOBIN
    Publication number: 20240076290
    Abstract: Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Application
    Filed: November 1, 2023
    Publication date: March 7, 2024
    Inventors: STEPHAN D. PARENT, TRAVIS LEE HOUSTON, COURTNEY S. JOHNSON, FANG WANG